News

Cash pay is 'going to constitute a major part of the Wegovy business': Novo Nordisk CFO
Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better ...
Wegovy maker Novo Nordisk warns on continued copycat-drug challenge as new CEO readied
Novo Nordisk cautioned on Wednesday that it expects continued competition this year from copycat versions of its Wegovy ...
Novo Nordisk Stock Catches a Downgrade. The Eli Lilly Threat Is Just One Reason.
Novo Nordisk stock was downgraded to Neutral from Buy by UBS analysts, who cited the threat posed by Eli Lilly as just one ...
Novo Nordisk stock downgraded as Trump teases 250% pharma tariffs
President Donald Trump says pharma tariffs could go as high as 250%. UBS downgrades Novo Nordisk stock to neutral and lowers ...
Novo Nordisk CEO warns of layoffs as Wegovy challenge heats up
Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could face layoffs as it battles rising pressure from main U.S. rival Eli Lilly , ...
Watch These Novo Nordisk Stock Price Levels After Last Week's 33% Drop
Novo Nordisk's U.S.-listed shares shed a third of their value last week after the company cut its full-year outlook and named ...
Novo Nordisk: I Was Wrong Twice, But This Selloff Looks Like 2016 All Over Again
Novo Nordisk is attractively valued after the sell-off, but near-term recovery requires patience. Read why I'm downgrading ...
Novo Nordisk Shares Plummet as Competition Weighs on Sales
The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.
Novo Nordisk reports second quarter earnings missing Wall Street estimates on slower GLP-1 sales
Novo Nordisk reported second quarter earnings a week after revising its 2025 outlook down on slower GLP-1 sales.